Catalyst Pharmaceuticals (CPRX) Retained Earnings (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Retained Earnings of $489.2 million for Q1 2026, up 1.93% on a QoQ basis from $480.0 million in Q4 2025, and up 2877852.94% year-over-year from N/an in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Retained Earnings (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at $489.2 million for Q1 2026.
- Quarterly Retained Earnings rose 2877852.94% year-over-year to $489.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $489.2 million (up 2877852.94% YoY) and the FY2025 annual result came in at $480.0 million, up 749832.81% from the prior year.
- Retained Earnings was $489.2 million for Q1 2026 at Catalyst Pharmaceuticals, up from $480.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $489.2 million in Q1 2026 and bottomed at -$453000.0 in Q1 2022.
- A 5-year average of $103.0 million and a median of $21500.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 251.35% — and 2026, when it surged 2877852.94%.
- Catalyst Pharmaceuticals' Retained Earnings stood at $24000.0 in 2022, then tumbled by 41.67% to $14000.0 in 2023, then surged by 357.14% to $64000.0 in 2024, then jumped by 749832.81% to $480.0 million in 2025, then grew by 1.93% to $489.2 million in 2026.
- Business Quant data shows CPRX's Retained Earnings at $489.2 million in Q1 2026, $480.0 million in Q4 2025, and $473.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 489.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 489.22 Mn |
| Dec 31, 2025 | 479.96 Mn |
| Sep 30, 2025 | 473.33 Mn |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 19,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 24,000.00 |
| Sep 30, 2022 | 32,000.00 |
| Jun 30, 2022 | -130,000.00 |
| Mar 31, 2022 | -453,000.00 |
| Dec 31, 2021 | -148,000.00 |
| Sep 30, 2021 | 231.17 Mn |
| Jun 30, 2021 | -37,000.00 |
| Mar 31, 2021 | -46.34 Mn |
| Dec 31, 2020 | -53.71 Mn |
| Sep 30, 2020 | -65.14 Mn |